ArticleScientific reports2025
Towards a harmonized testing strategy for nanofibers by integrating toxicological screening and proteomic profiling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Involvement of lysosomal proteins in morphology-driven toxicity of (nano)fibers.Archives of toxicology · 2026Review
- Proteomic Profiling of Alveolar Macrophages Identifies Loss of Lysosomal Content as an Indicator of Nanofiber-Induced Frustrated Phagocytosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanofibers, particularly multi-walled carbon nanotubes, have attracted attention for their exceptional properties, but concerns remain about their potential health hazards due to their fiber-like morphology. Although bio-durable nanofibers may cause cancer upon inhalation, only rigid nanofibers may exhibit morphology-driven pathogenicity. Since no validated methods exist for assessing their rigidity, alternative approaches are needed that comply with the 3R principles (Replacement, Reduction, Refinement) and the European Commission efforts to foster alternatives to animal testing. This study aims to advance the development of a harmonized test method for nanofibers toxicity by comparing effects of selected carbon-based nanomaterials (NMs) with different morphologies: a nanofiber (Mitsui-7-JRCNM40011a), an elongated material (NM-400) and a particle (Printex-90). Therefore, in vitro toxicological screening and proteomic investigations were employed using differentiated THP-1 (dTHP-1) macrophage-like cells. First, we evaluated cytotoxicity and pro-inflammatory responses of the different dTHP-1 phenotypes (M0, M1 and M2) to evaluate their sensitivity, and thus selected the M0 phenotype for further oxidative and lysosomal investigations: Mitsui-7-JRCNM40011a caused, besides increased cytotoxicity and pro-inflammatory effects, oxidative stress and lysosomal dysfunction. Moreover, decreased levels of 25 lysosomal proteins, including five cathepsins, were detected. These findings deepen the understanding of nanofiber-related toxicity, supporting the development of a reliable in vitro testing strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.